Nasdaq:US$15.16 (+0.08) | HKEX:HK$23.20 (-0.30) | AIM:£2.24 (-0.01)
Announcements
1
234567891011121314151617
found Documents: 833
Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 24, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED incl
Read More
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 22, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savo
Read More
Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 7, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2024 Annual Report, together with the Notice of Annual General Meeting and the Form
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 31, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that the ordinary resolution put to its Extraordinary General Meeting (“E
Read More
— First and only EZH2 inhibitor approved by the NMPA —   —HUTCHMED’s fourth product, and its first approval in hematological malignancies —   Hong Kong, Shanghai & Florham Park, NJ — Friday, March 21, 2025: HUTCHMED (C
Read More
Hong Kong, Shanghai & Florham Park, NJ  — Thursday, March 20, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who hav
Read More
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting
Read More
65% oncology products revenue growth drove profitable operation and supported new ATTC platform   Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2
Read More
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from a voluntary announcement released to the Stock Exchange of Hong Kong Limited on March 14, 2025. The text relates to the adoption of the 2025 Long Term Incentive Plan with e
Read More
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 14, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on Mar
Read More
Hong Kong, Shanghai & Florham Park, NJ —  Thursday, March 6, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)  today announces that it has completed enrollment of its a Phase II trial of fanregratinib (HMPL-453)
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 5, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independen
Read More
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on March 2, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Ex
Read More
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on February 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stoc
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 a
Read More
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock
Read More
— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval —   Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 14, 2025: HUTCH
Read More
Hong Kong, Shanghai & Florham Park, NJ — Thursday, January 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) a
Read More
INTRODUCTION On December 31, 2024, the Seller (a wholly-owned subsidiary of the Company) entered into: the GP Health SPA with GP Health Service Capital relating to the disposal of the GP Health Sale Shares, representing 35% equity interest in
Read More
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovat
Read More
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Cavendish Capital Markets Limited as its joint Corporate Broker in Lo
Read More
Hong Kong, Shanghai & Florham Park, NJ — Monday, December 30, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) announces the following blocklisting six monthly return:   1. N
Read More
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cance
Read More
Hong Kong, Shanghai & Florham Park, NJ — Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration
Read More
— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 3, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:
Read More
Hong Kong, Shanghai & Florham Park, NJ — Friday, November 29, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) hereby notifies the market that as at November 29, 2024, the issued share capital of HUTCHMED consiste
Read More
Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Admi
Read More
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States,
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 20, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independen
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 6, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as severa
Read More
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at October 31, 2024, the issued share capital of HUTCHMED consisted o
Read More
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today a
Read More
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on O
Read More
 — New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies
Read More
— First innovative oncology medicine ever to get enlisted in HA Drug Formulary directly under the Special Drug category — — First new drug approved by 1+ Mechanism listed in the Hospital Authority Drug Formulary — — Rapid enlistment and
Read More
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China —  
Read More